TN2013000420A1 - 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors - Google Patents

2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors

Info

Publication number: TN2013000420A1
Authority: TN; Tunisia
Prior art keywords: imidazol; pyridin; derivatives; amino; kinase inhibitors
Prior art date: 2011-05-20

Application number

TNP2013000420A

Other languages

English (en)

Inventor

Alain Braun

Olivier Duclos

Gilbert Lassalle

Franz Lorge

Valérie Martin

Olaf Ritzeler

Aurélie Strub

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-20

Filing date

2013-10-14

Publication date

2015-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44247865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000420(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-10-14 Application filed by Sanofi Sa filed Critical Sanofi Sa

2015-03-30 Publication of TN2013000420A1 publication Critical patent/TN2013000420A1/fr

Links

DBRZPAJZWZOTHY-UHFFFAOYSA-N 2-amino-3-(1h-imidazol-2-yl)-3h-pyridin-4-one Chemical class NC1=NC=CC(=O)C1C1=NC=CN1 DBRZPAJZWZOTHY-UHFFFAOYSA-N 0.000 title 1
108091008605 VEGF receptors Proteins 0.000 title 1
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TNP2013000420A 2011-05-20 2013-10-14 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors TN2013000420A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP11305624A EP2524915A1 (fr)	2011-05-20	2011-05-20	Dérivés de 2-amino-3-(imidazol-2-yl)-pyridin-4-one et leur utilisation en tant qu'inhibiteurs de kinase du récepteur VEGF
PCT/EP2012/059145 WO2012159959A1 (fr)	2011-05-20	2012-05-16	Dérivés de 2-amino-3-(inidazol-2-yl)-pyridine-4-one et utilisation de ceux-ci comme inhibiteurs de kinases associées au récepteur du vegf

Publications (1)

Publication Number	Publication Date
TN2013000420A1 true TN2013000420A1 (en)	2015-03-30

Family

ID=44247865

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000420A TN2013000420A1 (en)	2011-05-20	2013-10-14	2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors

Country Status (36)

Country	Link
US (2)	US9126972B2 (fr)
EP (2)	EP2524915A1 (fr)
JP (1)	JP5937201B2 (fr)
KR (1)	KR102005121B1 (fr)
CN (1)	CN103687852B (fr)
AR (1)	AR086451A1 (fr)
AU (1)	AU2012261077B2 (fr)
BR (1)	BR112013029820B1 (fr)
CA (1)	CA2833192C (fr)
CL (1)	CL2013003091A1 (fr)
CO (1)	CO6811857A2 (fr)
CR (1)	CR20130541A (fr)
CY (1)	CY1116720T1 (fr)
DK (1)	DK2709996T3 (fr)
DO (1)	DOP2013000241A (fr)
EA (1)	EA023580B1 (fr)
EC (1)	ECSP13013016A (fr)
ES (1)	ES2548266T3 (fr)
GT (1)	GT201300250A (fr)
HR (1)	HRP20150974T1 (fr)
HU (1)	HUE025111T2 (fr)
IL (1)	IL229210A0 (fr)
MA (1)	MA35196B1 (fr)
MX (1)	MX348842B (fr)
NI (1)	NI201300125A (fr)
PE (1)	PE20141527A1 (fr)
PH (1)	PH12013502303A1 (fr)
PL (1)	PL2709996T3 (fr)
PT (1)	PT2709996E (fr)
SG (1)	SG194204A1 (fr)
SI (1)	SI2709996T1 (fr)
TN (1)	TN2013000420A1 (fr)
TW (1)	TWI532740B (fr)
UA (1)	UA109942C2 (fr)
UY (1)	UY34082A (fr)
WO (1)	WO2012159959A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2952934B1 (fr) *	2009-11-23	2012-06-22	Sanofi Aventis	Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (fr)	2011-05-20	2012-11-21	Sanofi	Dérivés de 2-amino-3-(imidazol-2-yl)-pyridin-4-one et leur utilisation en tant qu'inhibiteurs de kinase du récepteur VEGF
SI2874625T1 (sl) *	2012-07-17	2017-10-30	Sanofi	Uporaba inhibitorjev VEGFR-3 za zdravljenje hepatoceličnega karcinoma
JOP20190086A1 (ar)	2016-10-21	2019-04-18	Novartis Ag	مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
MY199821A (en) *	2018-01-31	2023-11-23	Sanofi Sa	Modified lipidated relaxin b chain peptides and their therapeutic use
HU231285B1 (hu)	2018-04-18	2022-08-28	Printnet Kereskedelmi És Szolgáltató Kft.	A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
US20240158391A1 (en) *	2019-10-15	2024-05-16	Aucentra Therapeutics Pty Ltd	Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-yl) pyrimidin-2- amine for treating proliferative diseases and conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5919970A (en)	1997-04-24	1999-07-06	Allergan Sales, Inc.	Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7615565B2 (en)	2002-07-31	2009-11-10	Bayer Schering Pharma Aktiengesellschaft	VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
CN1191252C (zh) *	2003-08-11	2005-03-02	中国药科大学	3－位取代的喹诺酮衍生物及其在药学上的应用
JP4890255B2 (ja) *	2003-11-07	2012-03-07	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
KR100744826B1 (ko) *	2006-04-05	2007-08-01	한국화학연구원	이미다졸기가 치환된 퀴놀리논 유도체
EP2139888A2 (fr)	2007-03-28	2010-01-06	Array Biopharma, Inc.	Composés imidazoý1,2-a¨pyridine en tant qu'inhibiteurs de la tyrosine kinase récepteur
FR2917412B1 (fr)	2007-06-13	2009-08-21	Sanofi Aventis Sa	Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
WO2009053799A1 (fr) *	2007-10-24	2009-04-30	Glenmark Pharmaceuticals, S.A.	Nouveaux ligands du récepteur cannobinoïde, compositions pharmaceutiques les contenant et leur procédé de préparation
FR2933700B1 (fr) *	2008-07-08	2010-07-30	Sanofi Aventis	Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2010073078A2 (fr) *	2008-12-22	2010-07-01	Orchid Research Laboratories Ltd.	Composés hétérocycliques comme inhibiteurs de hdac
FR2952934B1 (fr)	2009-11-23	2012-06-22	Sanofi Aventis	Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (fr)	2011-05-20	2012-11-21	Sanofi	Dérivés de 2-amino-3-(imidazol-2-yl)-pyridin-4-one et leur utilisation en tant qu'inhibiteurs de kinase du récepteur VEGF
SI2874625T1 (sl) *	2012-07-17	2017-10-30	Sanofi	Uporaba inhibitorjev VEGFR-3 za zdravljenje hepatoceličnega karcinoma

2011
- 2011-05-20 EP EP11305624A patent/EP2524915A1/fr not_active Withdrawn
2012
- 2012-05-16 JP JP2014510800A patent/JP5937201B2/ja active Active
- 2012-05-16 DK DK12722347.7T patent/DK2709996T3/en active
- 2012-05-16 AU AU2012261077A patent/AU2012261077B2/en active Active
- 2012-05-16 CN CN201280035801.0A patent/CN103687852B/zh active Active
- 2012-05-16 MX MX2013013572A patent/MX348842B/es active IP Right Grant
- 2012-05-16 HU HUE12722347A patent/HUE025111T2/en unknown
- 2012-05-16 CA CA2833192A patent/CA2833192C/fr active Active
- 2012-05-16 UA UAA201314927A patent/UA109942C2/ru unknown
- 2012-05-16 ES ES12722347.7T patent/ES2548266T3/es active Active
- 2012-05-16 PE PE2013002448A patent/PE20141527A1/es not_active Application Discontinuation
- 2012-05-16 SI SI201230305T patent/SI2709996T1/sl unknown
- 2012-05-16 KR KR1020137030330A patent/KR102005121B1/ko active Active
- 2012-05-16 EP EP12722347.7A patent/EP2709996B1/fr active Active
- 2012-05-16 EA EA201391744A patent/EA023580B1/ru not_active IP Right Cessation
- 2012-05-16 PH PH1/2013/502303A patent/PH12013502303A1/en unknown
- 2012-05-16 WO PCT/EP2012/059145 patent/WO2012159959A1/fr active Application Filing
- 2012-05-16 SG SG2013077185A patent/SG194204A1/en unknown
- 2012-05-16 US US14/117,750 patent/US9126972B2/en active Active
- 2012-05-16 BR BR112013029820A patent/BR112013029820B1/pt active IP Right Grant
- 2012-05-16 PL PL12722347T patent/PL2709996T3/pl unknown
- 2012-05-16 PT PT127223477T patent/PT2709996E/pt unknown
- 2012-05-18 UY UY0001034082A patent/UY34082A/es not_active Application Discontinuation
- 2012-05-18 AR ARP120101766A patent/AR086451A1/es active IP Right Grant
- 2012-05-18 TW TW101117880A patent/TWI532740B/zh active
2013
- 2013-10-14 TN TNP2013000420A patent/TN2013000420A1/fr unknown
- 2013-10-15 DO DO2013000241A patent/DOP2013000241A/es unknown
- 2013-10-16 GT GT201300250A patent/GT201300250A/es unknown
- 2013-10-22 CR CR20130541A patent/CR20130541A/es unknown
- 2013-10-25 CL CL2013003091A patent/CL2013003091A1/es unknown
- 2013-11-03 IL IL229210A patent/IL229210A0/en active IP Right Grant
- 2013-11-08 EC ECSP13013016 patent/ECSP13013016A/es unknown
- 2013-11-19 NI NI201300125A patent/NI201300125A/es unknown
- 2013-11-20 CO CO13273134A patent/CO6811857A2/es active IP Right Grant
- 2013-12-18 MA MA36590A patent/MA35196B1/fr unknown
2015
- 2015-07-24 US US14/809,087 patent/US9675606B2/en active Active
- 2015-09-16 HR HRP20150974TT patent/HRP20150974T1/hr unknown
- 2015-09-24 CY CY20151100842T patent/CY1116720T1/el unknown

Also Published As

Publication number	Publication date
DOP2013000241A (es)	2013-12-31
CY1116720T1 (el)	2017-03-15
IL229210A0 (en)	2014-01-30
ES2548266T3 (es)	2015-10-15
TW201300386A (zh)	2013-01-01
PL2709996T3 (pl)	2015-12-31
WO2012159959A1 (fr)	2012-11-29
BR112013029820A2 (pt)	2016-12-06
CA2833192C (fr)	2019-10-22
MX2013013572A (es)	2014-01-16
NI201300125A (es)	2014-02-20
EP2524915A1 (fr)	2012-11-21
CN103687852B (zh)	2016-08-17
EA201391744A1 (ru)	2014-03-31
CL2013003091A1 (es)	2014-04-04
MA35196B1 (fr)	2014-06-02
AR086451A1 (es)	2013-12-11
HUE025111T2 (en)	2016-02-29
CN103687852A (zh)	2014-03-26
CA2833192A1 (fr)	2012-11-29
GT201300250A (es)	2015-03-05
DK2709996T3 (en)	2015-09-28
KR20140025465A (ko)	2014-03-04
PH12013502303A1 (en)	2014-01-06
UY34082A (es)	2013-01-03
EP2709996A1 (fr)	2014-03-26
PT2709996E (pt)	2015-10-16
NZ617931A (en)	2015-05-29
HRP20150974T1 (en)	2015-10-09
US9126972B2 (en)	2015-09-08
SI2709996T1 (sl)	2015-10-30
MX348842B (es)	2017-06-30
EP2709996B1 (fr)	2015-06-24
AU2012261077A1 (en)	2013-12-12
JP5937201B2 (ja)	2016-06-22
ECSP13013016A (es)	2013-12-31
US20140094488A1 (en)	2014-04-03
TWI532740B (zh)	2016-05-11
CR20130541A (es)	2013-12-09
EA023580B1 (ru)	2016-06-30
CO6811857A2 (es)	2013-12-16
AU2012261077B2 (en)	2016-05-05
JP2014513707A (ja)	2014-06-05
BR112013029820B1 (pt)	2020-02-04
UA109942C2 (ru)	2015-10-26
KR102005121B1 (ko)	2019-07-29
US20150328205A1 (en)	2015-11-19
SG194204A1 (en)	2013-12-30
US9675606B2 (en)	2017-06-13
PE20141527A1 (es)	2014-11-08

Publication	Publication Date	Title
PH12015501289B1 (en)	2019-02-13	Novel benzimidazole derivatives as ep4 antagonists
MX342161B (es)	2016-09-19	Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
MX2013012652A (es)	2014-05-27	Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
UA111075C2 (uk)	2016-03-25	Триазолопіридинові сполуки як інгібітори кінази рім
EA201400412A1 (ru)	2014-08-29	ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
MY175854A (en)	2020-07-14	Novel quinolone derivatives
TN2013000420A1 (en)	2015-03-30	2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors
MX2013008431A (es)	2013-08-12	Antagonista del receptor de mineralocorticoides.
EA201491376A1 (ru)	2015-01-30	Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
EA201491149A1 (ru)	2014-11-28	Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
IN2015DN01151A (fr)	2015-06-26
IN2015DN00372A (fr)	2015-06-12
PH12014501195A1 (en)	2014-09-01	Novel 2h-indazoles as ep2, receptor antagonists
MX2015000064A (es)	2015-04-08	Compuestos de acrilamida como ligandos receptores de histamina h3.
MX2014009084A (es)	2015-02-05	Derivados de pirimidooxazocina como inhibidores de mtor.
MX2015005312A (es)	2015-11-16	Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
PH12013502597A1 (en)	2018-04-11	Pyrazole derivatives useful as aldosterone synthase inhibitors
MX364929B (es)	2019-05-14	Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4.
UA108500C2 (ru)	2015-05-12	Неконкурентные антагонисты никотиновых рецепторов
UA110793C2 (uk)	2016-02-25	Піразолілхіноксалінові інгібітори кінази
PH12013501453A1 (en)	2013-08-28	Nicotinic receptor non-competitive antagonists
TN2013000456A1 (en)	2015-03-30	Pyrazole derivatives useful as aldosterone synthase inhibitors
UA110829C2 (uk)	2016-02-25	Похідні піразолу, придатні як інгібітори альдостеронсинтази